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Basal cell carcinoma: 10-year experience 
with electrochemotherapy
Luca G. Campana1,2*, Roberto Marconato3, Sara Valpione1,4, Sara Galuppo5, Mauro Alaibac6, Carlo R. Rossi1,2 
and Simone Mocellin1,2
Abstract 
Background: Electrochemotherapy (ECT), by combining manageable cytotoxic agents with short electric pulses, 
represents an effective palliative skin-directed therapy. The accumulated evidence indicates that ECT stands out as a 
safe and well-tolerated alternative treatment for patients with multiple or large basal cell carcinoma (BCC), who are 
not suitable for conventional treatments. However, long-term data and shared indications are lacking.
Methods: In this observational study, we retrospectively analyzed 84 prospectively collected patients with multiple, 
recurrent or locally advanced BCC who were not candidate for standard therapies and received bleomycin-based ECT 
according to the European Standard Operative Procedures of ECT, from 2006 to 2016.
Results: Disease extent was local, locally advanced and metastatic in 40 (48%), 41 (49%) and 3 (3%), respectively. 
Forty-four (52%) individuals had multiple BCCs. Grade 3 skin toxicity after ECT was observed in 6% of cases. Clearance 
rate was 50% (95% CI 39–61%). Primary presentation (p = 0.004), tumor size <3 cm (p < 0.001), well-defined borders 
(p = 0.021), absence of tumor ulceration (p = 0.001), non-aggressive BCC histology (p = 0.046) and age ≤69 years 
were associated with higher complete response rate. In patients with local BCC, the clearance rate was 72.5 and 85% 
after one or two ECT cycles, respectively. In the laBCC group, 32 patients (78%) achieved an objective response. Five-
year recurrence rate for local and laBCC was 20 and 38%, respectively (p ≤ 0.001).
Conclusions: One or two ECT cycles with bleomycin may be a valuable palliative treatment in well-selected patients 
with multiple BCCs and favorable tumor features. Validation of predictive factors will be imperative to match patients 
with optimal ECT treatment modalities. Management of laBCC with ECT warrants further investigation.
Trial registration ISRCTN14633165 Registered 24 March 2017 (retrospectively registered)
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Background
Basal cell carcinoma (BCC) represents the most common 
(~80%) form of skin cancer worldwide in white people 
and its incidence is rising in many countries, although 
it is not systematically reported in tumor registries [1]. 
Metastatic spread is extremely rare, but the incidence of 
locally advanced BCC (laBCC) has been estimated around 
8/100,000/year and is associated with substantial mor-
bidity, since most tumors occur in functional areas [2, 
3]. Excisional surgery and Mohs staged resection are the 
most effective treatments for low- and high-risk BCCs, 
respectively; radiotherapy, curettage and cautery, cryosur-
gery, carbon dioxide laser, photodynamic therapy, topical 
immunotherapy represent alternative options in selected 
cases [4]. Long-term outcomes are crucial in evaluating 
BCC treatments since it is a slow-growing cancer and 
recurrence may take long time before being clinically 
apparent. During the last decade, electrochemotherapy 
(ECT) has become an appreciated locoregional therapy 
in the field of dermato-oncology. ECT exerts its anti-
tumor effect through the permeabilization of cancer cells 
to chemotherapy by means of short, high-voltage, elec-
tric pulses which destabilize the cell membrane barrier, 
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allowing intracellular access of chemotherapeutic drugs 
that otherwise would not be able to penetrate the cell 
effectively [5]. Besides this permissive effect on chemo-
therapy, ECT exerts a complex vascular disrupting action, 
which may be usefully exploited when dealing with bleed-
ing tumors [6]. Drugs used in ECT, bleomycin or cisplatin, 
are cheap, easy to manage and generally safe. According 
to the European standard operative procedure of ECT 
(ESOPE), bleomycin can be administered either intratu-
morally or intravenously, according to the disease burden, 
while cisplatin can be injected intratumorally, in patients 
with few and small tumors [7]. Since the publication of 
the ESOPE in 2006, an increasing number of studies have 
provided evidence of ECT efficacy on different tumor his-
totypes [8–12]. On this basis, the National Institute for 
Health and Care Excellence (NICE) has recently recog-
nized ECT as a safe alternative option for BCC patients 
(NICE interventional procedure guidance [IPG478], pub-
lished date: February 2014). However, since the evidence 
basis is limited and established treatments provides high 
cure rates, clinicians involved in ECT are encouraged to 
systematically collect data on case selection, treatment 
parameters, patient outcomes and, possibly, to submit 
these data to the International Network for Sharing prac-
tices on Electrochemotherapy (InspECT) register (web-
site: http://www.insp-ect.org/) [13]. Although BCC is by 
far the most frequent skin cancer, clinical experience with 
ECT is still scarce [10–12, 14–18], probably due to the 
availability of several established treatment options [19]. 
In the present study, we sought to examine the feasibility, 
efficacy and toxicity of ECT in BCC and to gain insights 
into this potential field of ECT application.
Methods
Study population
An observational study was started in 2006 and con-
cluded in 2016 to analyze a 10-year experience with 
ECT in BCC patients referred to the Veneto Institute of 
Oncology. All consecutive patients who underwent ECT 
were included. Eligible subjects were aged 18  years or 
older and had histologically proven, measurable local, 
locally advanced or metastatic BCC. Patients with laBCC 
had to have at least one lesion >2 cm or any size plus ≥2 
risk features (21) so that surgical resection was deemed 
inappropriate (curative resection unlikely, substantial 
morbidity or deformity anticipated) by a plastic or head 
and neck surgeon. Moreover, laBCC had to be previously 
irradiated or, alternatively, radiation therapy had to be 
contraindicated or inappropriate (e.g. multifocal disease).
In order to be considered for ECT at our center, the 
patients with local BCC (≤2  cm with a maximum of 
1 risk feature) had to present at least two lesions when 
located in the face or at least three tumors when located 
in the other anatomical regions. All subject had to be dis-
cussed in the frame of a multidisciplinary team. Stand-
ard surgical resection was always considered as upfront 
treatment, when indicated. Other inclusion criteria were 
ECOG (Eastern Cooperative Oncology Group) perfor-
mance status 0–2, adequate bone marrow, hemoglobin 
and renal function (serum creatinine concentration no 
>1.5 time the upper normal limits), as well as normal res-
piratory capacity. Exclusion criteria were allergy or pre-
vious exposure to bleomycin at maximum recommended 
cumulative doses, radiological evidence of lung fibrosis, 
the presence of a pace-maker (for tumors on the chest 
wall), history of epilepsy, pregnancy, uncontrolled medi-
cal illness, concurrent oncological therapies except for 
endocrine manipulation, and unavailability for follow-
up visits. Patient management followed the standards of 
Good Clinical Practice (GCP). The local Ethic Commit-
tee granted approval for the study. All cases were dis-
cussed in the frame of a multidisciplinary team meeting. 
Patients gave written informed consent to the proce-
dure. Anesthesiology evaluation was performed only in 
patients scheduled under sedation or general anaesthesia. 
Tumor size (the largest diameter) was clinically measured 
for later response assessment.
Treatment
The ESOPE guidelines were followed in all patients [7]. 
Accordingly, the type of anaesthesia, the cytotoxic agent 
and its route of administration were chosen based on 
patient characteristics, disease extent and tumor ana-
tomical location. Systemic bleomycin (15,000  IU/m2) 
was administered intravenously as a 1-min bolus; alter-
natively, it was injected intratumorally on each lesion at 
a dosage of 250–1000  IU/cm3 of tumor. Electric pulses 
were applied by means of a needle electrode (Fig. 1) after 
8 or 1  min following intravenous or intratumoral bleo-
mycin administration, respectively. A current of 1.5 and 
1.0 Ampere (A) was considered surrogate of adequate 
tumor electroporation when using a hexagonal array or 
a linear array needle electrode, respectively [20]. A treat-
ment safety margin around tumor was not consistently 
adopted in these patients.
Follow‑up and response assessment
Patients were followed up at 1  week and at 1, 2, 6 and 
12  months thereafter. Subsequently, they were followed 
on a 6/12-month basis, according to disease extent, 
treatment outcome and risk of recurrence. Treated 
lesions were evaluated at 1 and 2 months by inspection 
and confirmed local response was classified as com-
plete response (CR), partial response (PR), stable dis-
ease (SD) or progressive disease (PD), in accordance 
with the Response Evaluation Criteria in Solid Tumors 
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(RECIST), adapted for the assessment of superficial dis-
ease [8, 9]. The patients who had residual disease (i.e., PR 
or SD) at 2-month follow-up were offered an additional 
ECT cycle. Development of additional BCCs also repre-
sented an indication to further ECT, when appropriate. 
Per-patient treatment success (assessed after the first and 
second ECT) required CR achievement and no relevant 
treatment-induced skin toxicity (i.e., no need of wound 
dressing). Per-patient treatment success at last follow-
up required absence of local recurrence/progression, no 
additional treatments for BCC, and the absence of ECT-
induced skin toxicity. Treated tumors were not routinely 
biopsied for pathological assessment.
Toxicity evaluation
Local and systemic toxicity was graded according to 
the Common Terminology Criteria for Adverse Events 
(CTCAE) [21].
Statistical analysis
Descriptive data are reported as number and percent-
age or median and range. Local progression-free survival 
(LPFS) was the interval from response achievement to 
disease recurrence or progression. Local response and 
tumor control were tabulated according to the relevant 
tumor characteristics and ECT parameters and were ana-
lyzed with the χ2 test or Mann–Whitney, according to the 
type of variables. Survival estimates were calculated with 
the Kaplan–Meier method and patient groups compared 
with the log-rank test. The analysis was adjusted for clus-
tering of lesions within patients. p < 0.05 was considered 
statistically significant for two-sided tests. Analysis was 
done using the R package (v3.0.1, CRAN Project, Vienna).
Results
Patient characteristics
Eighty-four patients (53 men, 31 women) with 185 BCCs 
were treated (Table  1). The median age at entry was 
69  years (range 24–89). All except one patient—who 
was heart-transplanted—had no history of immunosup-
pression. Patients had a median of two target lesions 
(range 1–13). Forty-one (49%) patients had a single BCC, 
while 43 (51%) patients presented with multiple tumors. 
Median size of the target lesions was 2.0 cm (range 0.5–
26.7). BCC distribution according to anatomical site is 
presented in Additional file 1: Figure S1.
Treatment procedure
One hundred ten ECT cycles were administered (Table 2; 
Additional file 2: Figure S2). The procedure was applica-
ble in all cases and all treated tumors received adequate 
electric currents. Eighteen (21.4%) patients received 
additional skin-directed treatments during the follow-up, 
due to incomplete response.
Toxicity
Within the first 24–48  h after treatment, painless ery-
thema and slight edema occurred at the site of elec-
trode insertion in all cases. Within 2 months from ECT, 
the median grade of patient-reported pain was 1 (range 
0–3). We observed some grade of skin toxicity in 53 
(63%) patients: G1, n = 35 (42%); G2, n = 10 (12%); G3, 
n = 5 (6%), G4, n = 3 (4%); all G3 and G4 toxicities were 
observed in patients who had ulcerated laBCC at base-
line. Sixteen (19%) patients experienced some form of 
ECT-induced skin ulceration (G1, n  =  14 patients; G2, 
n  =  2 patients). Ulceration appeared within the first 
week. Complete wound healing by second intention 
required an average of 4–8  weeks. One patient experi-
enced a wound infection on a locally advanced BCC of 
the trunk, which responded to oral antibiotics. At the 
last follow-up, none, except one, of these patients needed 
wound dressing. Only 6 out of 42 patients with ulcerated 
BCC at baseline, achieved wound healing at 2  months, 
however at the last follow-up 15/84 (18%) patients were 
requiring wound dressing for BCC, compared with 35/84 
(42%) at baseline (p  <  0.001). In patients with primary 
BCC (n = 42), the distribution of skin toxicity observed 
Fig. 1 Needle electrodes for tumor electroporation. The “finger” electrode (a); the linear array electrode (b); and the hexagonal array electrode (c)
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within 2 months after the first ECT was as follows: G0, 
23 (54.8%); G1, 15 (35.7%); G2, 3 (7.1%); G3, 1 (2.4%). In 
patients with recurrent BCC (n = 42), skin toxicity was as 
follows: G0, 8 (19%); G1, 20 (47.6%); G2, 7 (16.7%); G3, 4 
(9.5%); G4, 3 (7.1%).
Tumor response
Overall response rate after the first ECT cycle was 85.7% 
(72/84 patients) (95% confidence interval [CI] 78–93%). 
CR rate was 50% (42/84 patients) (95% CI 39–61%) 
(Additional file 3: Figure S3, Additional file 4: Figure S4). 
Treatment outcomes according to the investigated varia-
bles are reported in Table 3. Younger (≤69 years) patients 
achieved a higher CR rate compared with older ones. 
The CR rate was significantly higher in patients with 
primary than recurrent BCC as well as in patients with 
local BCC compared with laBCC. In BCCs  ≤3  cm the 
CR rate was 69.2%, while in tumors >3 cm it was 18.7% 
(p  <  0.001) (Additional file  5: Figure S5). Well-defined 
borders, non-aggressive histology and absence of ulcera-
tion also were significantly associated with CR achieve-
ment. In the subgroup of 24 patients who underwent a 
second ECT cycle, tumor response was as follows: CR, 11 
patients (45.8%); PR, 11 patients (45.8%); SD, 2 patients 
(8.4%). Overall, after the second ECT cycle CR rate 
increased from 50% (42/84) to 63% (53/84). In patients 
with local BCC (n =  40) tumor response after the first 
ECT cycle was as follows: CR, 29; PR, 10; SD, 1. Six of 
these patients underwent a second ECT cycle, achieving 
CR (n = 5) and PR (n = 1). Accordingly, in patients with 
Table 1 Patient characteristics (N = 84)
Characteristics N (%) or median (range)
Sex
 Male/female 53 (63)/31 (37)
Age (years) 69 (24–89)
Comorbiditiesa (n) 2 (0–6)
Performance status (ECOG) 2 (0–3)
Location of BCC
 Head and neck 52 (62)
 Trunk 23 (27)
 Limbs 9 (11)
Risk of tumor location
 Highb 19 (23)
 Intermediatec 33 (39)
 Lowd 32 (38)
Involvement of multiple anatomical sites
 Yes/no 20 (24)/64 (76)
TNM
 T1 33 (39)
 T2b 49 (58)
 T3 2 (2)
Tumor size
 ≤3 cm/>3 cm 52 (62)/32 (38)
Presentation
 Primary/recurrent 42 (50)/42 (50)
Disease extent
 Local 40 (48)
 Locally-advanced 41 (49)
 Metastatic 3 (3)
Histotype
 Aggressive/non-aggressivec 15 (18)/69 (82)
Marginse
 Defined/ill-defined 64 (76)/20 (24)
Ulceration
 Yes/no 42 (50)/42 (50)
Bleeding
 Yes/no 11 (13)/73 (87)
Distant metastases
 Yes/no 3 (4)/81 (96)
Need of dressings
 Yes/no 35 (42)/49 (58)
Previous treatments
 Surgical excision 39 (46)
 Radiotherapy 20 (24)
 Systemicd 6 (7)
 Other dermatologic  treatmentsf 8 (9)
Contraindications to surgery
 None 30 (36)
 Multiple recurrences 11 (13)
 Expected morbidity 43 (51)
a Comorbidities were grouped into the following categories: vascular disease 
(n = 48, 57.1%); cancer, excluding non-melanoma skin cancer (n = 46, 54.8%), 
endocrine (n = 25, 29.8%), renal (n = 16, 19.0%), neurologic (n = 9, 10.8%), 
cardiac (n = 9, 10.8%), hepatic (n = 8, 9.5%), lung (n = 8, 9.5%), gastrointestinal 
(n = 7, 8.3%); one patient had xeroderma pigmentosum
b T2a (n = 32), T2b (n = 17)
c Aggressive histotypes included infiltrative and morpheiform BCC; non-
aggressive histotypes included superficial and nodular BCC
d Vismodegib
e The classification was dependent upon the surgeon’s judgment. The BCCs 
with well-defined borders were those lesions for which the trajectory of a 
hypothetical surgical incision could unequivocally be individuated. All the other 
BCCs, in which clinical margins were difficult to distinguish from uninvolved 
skin were included in the ill-defined margins group (e.g. absence of uniform, 
well-raised borders, some pigmented BCCs, and some morpheaform BCCs, along 
with some BCCs previously managed with local treatments)
f Cryotherapy (n = 5), PDT (n = 2), imiquimod (n = 1)
Table 1 continued
Characteristics N (%) or median (range)
Contraindications to radiotherapy
 None 23 (27)
 Previous radiotherapy 19 (23)
 Radiotherapy inappropriate 42 (50)
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local BCC, the clearance rate after the first and the sec-
ond ECT cycle was 72.5 and 85%, respectively. Finally, we 
observed a higher CR rate in patients who received intra-
tumoral compared with intravenous bleomycin (62.7% vs 
32.3%, p = 0.005). Moreover, CR rate decreased with the 
increasing electrode size: finger 75%, linear array 54.3%, 
hexagonal array 30.8% (p = 0.027) (Table 3).
Among the BCCs of the head and neck region, the 
clearance rate according to anatomical location was as 
follows: ear (n = 16) 25%; periorbital (n = 2) 50%; nose 
(n = 19) 52.6%; neck (n = 7) 57.1%; cheek (n = 22) 59.1%; 
scalp (n  =  40 tumors) 62.5%; forehead (n  =  9) 66.7%; 
lip (n = 3) 100%. We observed a significantly higher CR 
rate among BCCs located on the scalp when compared 
to all the other locations of the head and neck district 
(p = 0.03).
Tumor control
Median follow-up time was 49.2  months (range 3.6–
121.1). Treatment failure was documented in 17 out 
of the 84 (20.2%) patients, after a median of 22 months 
(range 6.8–55.2). Eleven of these 17 patients relapsed 
after a single ECT session (3 patients achieved CR, 8 PR); 
the remaining 6 patients had initially received 2 ECT 
cycles (4 patients achieving PR, 2 SD). The remaining 67 
patients were free from local recurrence or progression at 
last follow-up. Of these 67 patients, 6 were still requiring 
some kind of wound dressing at the last evaluation (Addi-
tional file 5: Figure S5). Five of these patients received a 
single ECT (4 PRs, 1 SD) and one patient 2 ECT cycles, 
achieving SD and then PR; the latter patient received also 
imiquimod and radiotherapy after ECT, achieving PR.
Treatment success rate following the first and the sec-
ond ECT cycle as well as at the last follow-up was 40.5% 
(34/84 patients), 51.2% (43/84 patients) and 65.5% (55/84 
patients), respectively (p  =  0.005). Five-year LPFS was 
70% (95% CI 58–82%). The following clinical and proce-
dural factors were associated with better tumor control: 
local disease extent (p  <  0.001), non-aggressive histol-
ogy (p =  0.016), tumor size ≤3 cm (p < 0.001), T1 stage 
(p  =  0.036), well-defined borders (p  <  0.001), absence 
of ulceration (p  <  0.001) (Table  3; Fig.  2). Finally, we 
observed that patients who received intratumoral bleo-
mycin achieved better tumor control compared with 
those treated with intravenous bleomycin (median LPFS, 
41.7 months [range 2.2–118.4] vs 14.5 months [range 3.5–
112.5], p = 0.007). Moreover, median LPFS decreased with 
the increasing size of the electrode: finger 41.5  months 
(range 17.3–87.9), linear array 26.8 (range 2.2–118.4), hex-
agonal array 20.6 (range 3.5–113.1) (p = 0.423).
Twenty-four patients (28.6%) received a second ECT 
cycle. In this group, the recurrence rate was 25% (6 out of 
24 patients), compared with 18.3% (11 out of 60 patients) 
in the group that received a single ECT, but this finding 
likely reflects the more unfavorable characteristics (larger 
size) of tumors that were treated twice. When splitting 
patients according to disease extent (e.g. local vs laBCC), 
the benefit of retreatment was more evident in patients 
with local BCC. In this subgroup (n =  40 patients), the 
recurrence rate was 17.6% (6/34 patients) after a single 
ECT cycle and 0% (0/6 patients) after two ECT cycles 
(p  =  0.264). In patients with locally-advanced disease, 
the recurrence rate was 19.2% (5/26 patients) and 26.7% 
(4/15 patients) after one or two ECT cycles, respectively 
(p = 0.579). The recurrence rate according to BCC pres-
entation was as follows: primary BCC, 14.3% (6 out 42 
patients); recurrent BCC, 26.2% (11 out 42 patients), 
p =  0.174. Accordingly, 5-year recurrence rate for local 
and laBCC were 20 and 38%, respectively.
Patient outcome
During follow-up, 16 (19%) patients were diagnosed with 
additional skin cancers. Ten out 84 (12%) patients devel-
oped further BCCs and four of them received additional 
ECT cycles (3 achieved CR, 1 PR). Additional skin cancer 
diagnoses included melanoma (n = 7) and SCC (n = 3).
Table 2 Electrochemotherapy parameters
ECT electrochemotherapy, BLM bleomycin
a The second ECT cycle was administered after a median interval of 3 months 
(range 2–22)
b See Fig. 2 for electrode characteristics
c Further treatments (administered at least 2 months after ECT) included the 
following: radiotherapy (n = 9 patients), surgery (n = 4 patients), imiquimod 
(n = 3 patients), vismodegib (n = 3 patients), local 5-FU (n = 2 patients), 
cryotherapy (n = 1 patient), laser (n = 1 patient), chemotherapy (n = 1 patient)
Characteristics No (%)
No of ECT cycles
 1 60 (71.4)
 2a 23 (27.4)
 4 1 (1.2)
Anesthesia
 Local 31 (36.9)
 Sedation 11 (13.1)
 Local + sedation 40 (47.6)
 General 2 (2.4)
Route of BLM administration
 Intratumoral 51 (60.7)
 Intravenous 33 (39.3)
Electrodeb
 Finger 12 (14.2)
 Linear 46 (54.8)
 Hexagonal 26 (31)
Further  treatmentsc
 Yesc 18 (21.4)
 No 66 (78.6)
Page 6 of 12Campana et al. J Transl Med  (2017) 15:122 
Table 3 Treatment outcome according to tumor characteristics in 84 patients with basal cell carcinoma treated by elec-
trochemotherapy
Italic values indicate significance of p value (p < 0.05)
CR complete response, LPFS local progression-free survival, mos months, PS performance status, ECOG Eastern Cooperative Oncology Group, BCC basal cell carcinoma, 
adv advanced, BLM bleomycin
a Low risk locations: trunk and extremities; intermediate risk locations: cheeks, forehead, scalp, neck; high risk locations: central face, eyelids, peri-orbital, nose, lips, 
chin, mandible, ear, pre-/post-auricular, genitalia, hands and feet
Variable Response  
rate, n (%)
p CR rate
n (%)
p LPFS (mos),  
median (range)
p 5‑year recurrence 
rate,  %
Age at first ECT 0.756 0.048 0.077
 ≤69 (n = 42) 37 (88.1%) 27 (64.3%) 35.0 (2.2–120.1) –
 ≥70 (n = 42) 35 (83.3%) 15 (35.7%) 23.3 (3.6–114.8)
PS (ECOG) 0.760 0.512 0.134
 0–1 (n = 40) 35 (87.5%) 18 (45%) 39.7 (2.2–120.1) –
 2–3 (n = 44) 37 (84.1%) 24 (54.5%) 24.7 (6.8–114.5)
No of comorbidities 1 0.826 0.183
 0–2 (n = 46) 39 (84.8%) 24 (52.2%) 39.0 (2.2–114.8) –
 3–6 (n = 38) 33 (86.8%) 18 (47.4%) 27.2 (2.2–120.1)
Presentation 0.244 0.004 0.141
 Primary (n = 42) 38 (90.5) 28 (66.7) 34.2 (2.2–118.4) –
 Recurrent (n = 42) 34 (80.9) 14 (33.3) 29.1 (3.5–113.1)
BCC extent 0.001 <0.001 <0.001
 Local (n = 40) 39 (97.5) 29 (72.5) 38.9 (2.2–110.0) 20
 Locally-adv (n = 41) 32 (78.0) 13 (31.7) 23.0 (3.5–118.4) 38
Aggressive histology 0.006 0.046 0.016
 Yes (n = 15) 9 (60) 4 (26.7) 21 (3.5–107.9) 52
 No (n = 69) 63 (91.3) 38 (55.1) 33·7 (4.7–118.4) 24
T size <0.001 <0.001 <0.001
 ≤3 cm (n = 52) 52 (100) 36 (69.2) 44.3 (2.2–118.4) 20
 >3 cm (n = 32) 20 (62.5) 6 (18.7) 11.5 (3.5–112.5) 58
Ill-defined borders <0.001 0.021 <0.001
 Yes (n = 20) 12 (60) 5 (25) 11.2 (3.5–107.9) 68
 No (n = 64) 60 (93·7) 37 (57.8) 40.75 (2.2–118.4) 22
Location  riska 0.728 0.436 0.212
 Low (n = 32) 29 (90.6) 19 (59.4) 31 (15.5–118.4) –
 Intermediate (n = 33) 26 (78.8) 14 (42.4) 21.0 (4.7–107.9)
 High (n = 19) 17 (89.5) 9 (47.4) 48.7 (6.7–75.3)
Ulceration 0.005 0.001 <0.001
 Yes (n = 42) 31 (73.8) 13 (30.9) 21.3 (3.5–118.4) 52
 No (n = 42) 41 (97.6) 29 (69) 43.0 (2.2–113.1) 12
TNM <0.001 <0.001 0.174 
 T1 (n = 32) 32 (100) 26 (81.2) 41.5 (2.2–113.1) –
 T2 (n = 50) 40 (80) 16 (32) 22.9 (3.5–118.4)
 T3 (n = 2) 0 (0) 0 (0) 7.0 (6.8–7.3)
BLM route 0.002 0.005 0.007
 i.t. (n = 51) 49 (96.1) 32 (62.7) 41.7 (2.2–118.4) –
 i.v. (n = 33) 23 (69.7) 10 (30.3) 14.5 (3.5–112.5)
Electrode 0.05 0.027 0.423 
 Finger (n = 12) 12 (100) 9 (75) 41.5 (17.3–87.9) –
 Linear (n = 46) 41 (89.1) 25 (54.3) 26.8 (2.2–118.4)
 Hexagonal (n = 26) 19 (73.1) 8 (30.8) 20.6 (3.5–113.1)
Page 7 of 12Campana et al. J Transl Med  (2017) 15:122 
Fig. 2 Local tumor control in 84 patients with basal cell carcinoma treated by electrochemotherapy. Local progression-free survival in the whole 
study population (a) and according to disease extent (b), tumor size (c), ulceration (d), tumor borders (e), and histology (f)
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Discussion
As the prevalence of BCC rises with aging of the popu-
lation, clinicians involved in BCC treatment face an 
increasing number of challenging scenarios. These are 
the patients with laBCC, hereditary basal cell naevus 
syndrome, and those with multiple or recurrent BCCs, 
who are compelled to undergo multiple interventions. 
Although these patients represent only a small propor-
tion of the overall BCC population, nonetheless the bur-
den of disease prompts for new evidence-based therapies 
especially for those individuals who are not amenable to 
surgical treatment (i.e., excision would be disfiguring or 
unpractical). In the present study, which is based on the 
largest available BCC series managed by ECT, we evalu-
ated 84 subjects who were treated according to a stand-
ardized protocol (ESOPE) [7]. Since ECT indications 
were restrictive, our study population has at least two 
peculiar characteristics: the high number of subjects with 
relevant comorbidities (Table 1), and the high percentage 
of laBCCs (49%). Since the presence of comorbidities has 
been shown to impact on the survival of elderly patients, 
especially for less lethal cancers [22], a minimally inva-
sive, low-demanding treatment modality can be consid-
ered a reasonable alternative in well-selected cases. The 
simplicity of treatment application, the ability to simul-
taneously treat multiple lesions (Additional file  4: Fig-
ure S4) coupled with high patient tolerability, represent 
potential advantages of ECT in patients with multifocal 
or laBCC or in presence of diseases that limit the number 
of practicable therapies [17].
Electrochemotherapy was successfully applied in 
all cases, with no serious adverse events. Overall, we 
observed a 50% CR rate after a single ECT cycle, with sig-
nificantly higher clearance rates in younger patients with 
primary BCC presentation, local tumor extent, small 
tumor size, well-defined borders, absence of ulceration 
and non-aggressive histology. Overall, local recurrence 
occurred in 20% of patients (primary BCC, 14%; recur-
rent BCC, 26%) and ECT-induced toxicity was observed 
in 19% of patients, being mild and transient in most 
cases. Noteworthy, we reported a significant decrease 
(from 42 to 18%) in the fraction of patients who required 
wound dressing during the follow-up. This is a relevant 
observation since BCC, and especially advanced BCC, is 
associated with a significant disease burden and health 
care resource utilization. The same parameters that were 
associated with CR achievement—with the exception of 
BCC presentation and TNM classification—were also 
associated with longer tumor control. Some of these vari-
ables support the notion of tumor response dependency 
upon tumor size in ECT, as previously observed by other 
authors [8, 9, 23]. Interestingly, BCCs with ill-defined 
borders were less responsive to treatment. For this 
reason, we advocate the adoption and quantification of 
predefined treatment safety margins as a valuable meas-
ure to minimize the risk of recurrence from subclinical 
tumor deposits [13]. In this regard, general anesthesia—
together with no previous surgical treatment—was found 
to be associated with significantly higher CR rate in 
patients with non-melanoma head and neck skin cancers 
who underwent ECT according to a recent multicenter 
phase II study including 55 individuals, of whom 24 with 
BCC [24]. This observation raises the hypothesis that 
general anesthesia may ensure better treatment tolerabil-
ity by patients and thus a more accurate tumor coverage 
with electrode placements during the procedure.
In addition, in our study the patients with aggressive 
BCC histotypes proved to be less responsive; therefore, 
BCC-specific histopathological parameters should be 
taken into account in future studies in order to refine 
patient selection. Finally, we correlated treatment out-
come with ECT procedural parameters, but these obser-
vations are likely biased by differences in BCC size [7]. 
Accordingly, the identification of the best route of drug 
administration as well as the most suitable electrode type 
in ECT will require a dedicated study with more homo-
geneous tumor groups.
It should be noted that currently available ECT guide-
lines [7] mainly refer to the feasibility of the procedure 
itself, but are not informative about the appropriate-
ness of treatment indication or the optimal number of 
treatment cycles. These aspects need to be elucidated 
in future studies. According to our experience, a second 
ECT cycle increased the CR rate from 50 to 63% and 
retreatment was more advantageous in patients with 
local BCC, in whom CR rate increased from 72.5 to 85%. 
However, numbers are small and these findings should 
be evaluated with caution. For instance, the benefit of 
retreatment has been observed in BCC treated by 5-ami-
nolaevulinic acid photodynamic therapy. In a longitudi-
nal, non-randomized study on 44 patients with primary 
or recurrent BCC, Christensen et al. [25] reported a CR 
rate of 60 and 87% after one or two treatment sessions, 
respectively. For the time being, retreatment with ECT 
seems a reasonable option in patients with small BCCs in 
order to consolidate response duration, particularly when 
risk factors such as aggressive histology, ill-defined bor-
ders or ulceration are present (Table 3).
Our results appear less satisfactory as compared to 
the literature data on BCC treatment with ECT [24]. It 
is remarkable that no comparative trials have been car-
ried out so far and no cost-analyses are available. The 
bulk of the literature consists of small observational 
series, often including heterogeneous skin cancers [10, 
12, 14–18, 24]. In an early trial, Glass et al. [16] reported 
a 98% response rate after one or more ECT cycles with 
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intralesional bleomycin and no recurrences detected 
after 18  months. However, this trial, which adopted a 
different electroporation protocol, enrolled exclusively 
patients with sporadic BCC and low tumor size (mean 
diameter 0.91 cm, range 0.37–2.1). A recent meta-analy-
sis assessing 47 prospective studies on patients with cuta-
neous metastases—mainly from melanoma and breast 
cancer—treated by skin-directed therapies (including 
ECT, radiation, photodynamic, intralesional and topical 
therapies) showed sustained response rates across treat-
ments with G ≥ 3 dermatological toxicity in less than 6% 
of patients [26]. More recently, a European and an Italian 
multicenter studies (both adopting the ESOPE protocol), 
have reported CR rates of 91 and 66.7%, respectively, in 
BCC patients, although with a short follow-up (6 and 
13.9  months, respectively) [10, 11]. In 2016, Rotunno 
et al. reported a 75% CR rate in patients with head and 
neck BCC treated by ECT. The majority (42%) of these 
tumors (whose median size was 24  mm) were located 
on the scalp and half of patients required at least 2 ECT 
cycles [24]. An ongoing randomized trial is currently 
evaluating treatment durability of surgical excision versus 
ECT in patients with primary BCC. An interim analysis, 
based on 86 patients at 3-year follow-up, indicates com-
parable efficacy, as indicated by local disease-free pro-
gression of 97 and 92%, respectively (p = 0.37) [27].
Recurrence rates in primary and recurrent BCC treated 
by conventional treatments can be summarized as fol-
lows: excisional surgery, 2–17.4% [28–31]; Mohs surgery, 
1.0–5.6% [28, 32]; curettage and electrodessication, 7.7–
40% [28, 33]; cryotherapy, 7.5–13% [28, 32]; radiotherapy, 
7.4–16% [28, 32, 34, 35]. Topical immunotherapy with 
imiquimod ensures 5-year recurrence rate around 20% in 
small superficial BCC [36]. Finally, recurrence rate after 
photodynamic therapy, in its various forms of ALA-PDT 
(aminolevulinic acid photodynamic therapy) and MAL-
PDT (methyl aminolevulinate photodynamic therapy), 
ranges to 18–22% [37, 38]. Taken together, these data 
indicate that ECT has an acceptable toxicity profile, 
but a higher recurrence rate, especially when compared 
with excisional and Mohs surgery. In the present study, 
5-year recurrence rate in local and laBCC was 20 and 
38%, respectively. There are same possible explanations 
for these findings. First, we cannot exclude suboptimal 
treatment delivery. ECT exerts its effect when tumors 
are simultaneously exposed to chemotherapy and elec-
tric fields. In this regard, BCC poses peculiar challenges. 
More than 60% of our patients had tumors located on the 
head and neck region, where direct drug injection can 
lead to inhomogeneous distribution or to spillage from 
the injection site, as previously observed [39]. Further, 
we hypothesize that the diffusion of chemotherapy in 
tumor tissue may have been hampered by the presence 
of scars from previous treatments, thus leading to inho-
mogeneous drug distribution [24]. Second, it is possible 
that some tumors could have been covered sub optimally 
by electric pulses. Since 36.9% of patients were managed 
under local anesthesia only, it is likely that sedation or 
general anesthesia would have allowed a deeper (e.g. in 
laBCCs) or wider (e.g. in BCCs with ill-defined borders) 
electrode application [24]. In support of this hypothesis, 
it is worthy to note that in the present series 20 out of 
84 patients had tumors with clinically ill-defined bor-
ders and that these tumors had the highest recurrence 
rate (Table  3). A third explanation may reside in tumor 
biology. In fact, the fraction of replicating cells in BCC is 
low [40] and cytotoxic agents, which selectively kill the 
actively replicating cells, exert their action on a small 
fraction of them. Finally, the relatively long follow-up of 
our study allowed for the detection of late recurrences.
Surgical treatment definitely represents the preferred 
options for BCC, with conventional excision being suf-
ficient in most primary BCCs and Mohs micrographic 
surgery being the most effective in high risk or recur-
rent BCCs of the face, where it is associated with 5- and 
10-year recurrence rates of 2.1–5.2% and 3.9–4.4%, 
respectively [41–43]. Among non-surgical options, radi-
otherapy represents a consolidated and effective alter-
native [3, 4, 34, 35], although logistical barrier may be a 
limitation. In selected cases, ECT may be a rapid, easy to 
apply treatment, although the broad spectrum of BCC 
presentation poses peculiar challenges to its applica-
tion. In order to maximize the efficacy to toxicity ratio, 
clinicians should aim to select the most appropriate ECT 
treatment modality (type of anaesthesia, route of drug 
administration and electrode geometry). In theory, sys-
temic chemotherapy, coupled with use of a large needle 
electrode (i.e., the hexagonal array, Fig. 1a) allows homo-
geneous tumor tissue exposure to chemotherapy and 
complete tumor electroporation. However, this should 
be weighed against possible side effects. Systemic bleo-
mycin can be associated, although in very rare cases, 
with lung toxicity (especially in patients >70 years of age) 
[44], and the application of a large needle electrode can 
increase skin injury due to its greater invasiveness [39]. 
Furthermore, clinician and patients could be reluctant to 
systemic chemotherapy for the treatment of a localized, 
slow growing tumor. ECT proved to be effective in BCCs 
located on the midface, where treatment could be poten-
tially challenging due to the presence of aesthetic and 
functional structures. According to a well-documented 
series of three patients with BCC of 0.5–1.0 cm2 affecting 
the peri-ocular region, treatment with ECT is feasible, 
safe and associated with acceptable scarring [18].
Interestingly, we observed a 31.7% CR rate in laBCC 
(Table 3), with appreciable tumor shrinkage also in partial 
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responders (Additional file 5: Figure S5). Only a few stud-
ies of chemotherapy in BCC have been published and 
most of them found a relative unresponsiveness, except 
for limited success with cisplatin [45]. We did not per-
form cisplatin-based ECT, since, according to the ESOPE, 
this drug is currently codified for intratumoural injection 
only, and specifically in small size tumors [7]. Although 
the laBCC field has successfully entered the era of targeted 
therapy, locoregional treatments continue to be worth of 
consideration, particularly in the frame of integrated strat-
egies. CR rates ranging from 21 to 34% have been consist-
ently observed with the hedgehog inhibitor vismodegib, 
with median PFS ranging from 9.5 to 24.5  months [46, 
47]. However, tolerability still represents a tangible obsta-
cle in continuation of therapy, with 10–25% of patients 
requesting to stop treatment and 36% discontinuing due to 
adverse events (mainly muscle spasms, alopecia and dys-
geusia) [46, 47]. In this context, local treatment with ECT 
could be rationally associated or combined (e.g. during the 
so-called drug holidays) with target therapy in order to 
maximize or consolidate tumor response. However, for the 
time being, the limited experience does not allow general 
recommendations, therefore prospective trials are war-
ranted to assess the impact of ECT in advanced BCC.
Although non-comparative, the present study has 
some strengths. It is based on a relatively large series. It 
included BCC-specific parameters (histological subtypes, 
tumor borders, ulceration) in order to personalize treat-
ment indication. It was conducted at a center, which is 
long acquainted with the procedure [8, 9, 11, 39]. Finally, 
it has a relatively long follow-up, which is crucial for 
assessing late recurrences [28, 43]. Nevertheless, we also 
acknowledge a number of limitations. First, this study is 
not comparative. Second, we included patients with het-
erogeneous BCC types and adopted a conservative defi-
nition for laBCC. Third, tumor response was clinically 
assessed, and thus possibly overestimated, with no inde-
pendent review assessment. Fourth, we did not apply treat-
ment safety margins around the target tumor in all cases. 
Finally, patient-reported outcomes and functional as well as 
cosmetic results were not included. It is desirable that dis-
ease-specific questionnaires will be incorporated in future 
studies together with 5- and 10-year follow-up data.
Conclusions
We tested ECT as a palliative alternative treatment in 
a challenging cohort of patients with relevant comor-
bidities and a high percentage of recurrent or laBCC. 
One or two ECT cycles eradicated treated tumors in 
50 and 63% of patients, respectively, with limited tox-
icity. Large tumor size, recurrent presentation, locally 
advanced disease, aggressive BCC histology, ill-defined 
borders and tumor ulceration were limiting factors to CR 
achievement. These factors can be overcome by a second 
ECT cycle, at least in patients with small BCC. In those 
with laBCCs, ECT provides effective tumor control, but 
the optimal number of treatment cycles, patient compli-
ance and possible combined approaches with targeted 
therapy remain to be established. Validation of predictive 
factors is imperative in order to match each single BCC 
patient with the most suitable ECT treatment modalities. 
Ongoing and future trials will help to clarify the role of 
ECT in the treatment algorithm of BCC patients.
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